Diabetes type1

Metabolic Diseases
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
Semaglutide Pen InjectorPhase 2Peptide1 trial
Active Trials
NCT06411210Recruiting54Est. Jun 2028
Precigen
PrecigenGERMANTOWN, MD
1 program
1
AG019 - Low DosePhase 1/21 trial
Active Trials
NCT03751007Completed45Est. Oct 2021
Alliance Pharmaceuticals
1 program
Device: Actiste 1.0 and the Companion app with TBL BackendN/A1 trial
Active Trials
NCT05284071Completed13Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Novo NordiskSemaglutide Pen Injector
PrecigenAG019 - Low Dose
Alliance PharmaceuticalsDevice: Actiste 1.0 and the Companion app with TBL Backend

Clinical Trials (3)

Total enrollment: 112 patients across 3 trials

NCT06411210Novo NordiskSemaglutide Pen Injector

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Start: Jul 2024Est. completion: Jun 202854 patients
Phase 2Recruiting
NCT03751007PrecigenAG019 - Low Dose

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

Start: Oct 2018Est. completion: Oct 202145 patients
Phase 1/2Completed
NCT05284071Alliance PharmaceuticalsDevice: Actiste 1.0 and the Companion app with TBL Backend

Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation

Start: Mar 2022Est. completion: Dec 202213 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 112 patients
3 companies competing in this space